Livzon Pharmac Grp Stock Current Liabilities
| LP6 Stock | EUR 3.40 0.20 6.25% |
LIVZON PHARMAC GRP fundamentals help investors to digest information that contributes to LIVZON PHARMAC's financial success or failures. It also enables traders to predict the movement of LIVZON Stock. The fundamental analysis module provides a way to measure LIVZON PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to LIVZON PHARMAC stock.
LIVZON |
LIVZON PHARMAC GRP Company Current Liabilities Analysis
LIVZON PHARMAC's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, LIVZON PHARMAC GRP has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
LIVZON Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0514 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.15 % | |||
| Shares Outstanding | 309.83 M | |||
| Shares Owned By Insiders | 52.73 % | |||
| Shares Owned By Institutions | 14.83 % | |||
| Price To Earning | 4.02 X | |||
| Revenue | 12.18 B | |||
| Gross Profit | 7.75 B | |||
| EBITDA | 2.3 B | |||
| Net Income | 684.16 M | |||
| Cash And Equivalents | 1.14 B | |||
| Cash Per Share | 1.58 X | |||
| Total Debt | 22.97 M | |||
| Debt To Equity | 1.30 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 14.37 X | |||
| Cash Flow From Operations | 192.47 M | |||
| Earnings Per Share | 0.27 X | |||
| Number Of Employees | 8.58 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 3.86 B | |||
| Annual Yield | 0.06 % | |||
| Last Dividend Paid | 1.3 |
About LIVZON PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LIVZON PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LIVZON PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LIVZON PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in LIVZON Stock
LIVZON PHARMAC financial ratios help investors to determine whether LIVZON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in LIVZON with respect to the benefits of owning LIVZON PHARMAC security.